MCID: INT079
MIFTS: 56

Intrahepatic Cholangiocarcinoma malady

Categories: Rare diseases, Cancer diseases, Gastrointestinal diseases, Liver diseases

Aliases & Classifications for Intrahepatic Cholangiocarcinoma

About this section

Aliases & Descriptions for Intrahepatic Cholangiocarcinoma:

Name: Intrahepatic Cholangiocarcinoma 11 48 13 68
Cholangiocarcinoma 39 68
Peripheral Intrahepatic Cholangiocarcinoma 68
 
Intrahepatic Bile Duct Carcinoma 11
Peripheral Cholangiocarcinoma 11

Classifications:



External Ids:

Disease Ontology11 DOID:4928
ICD1030 C22.1
SNOMED-CT62 109842005
MeSH39 D018281
NCIt45 C35417

Summaries for Intrahepatic Cholangiocarcinoma

About this section
NIH Rare Diseases:48 Intrahepatic cholangiocarcinoma is a cancer that develops in the cells within the bile ducts; both inside and outside the liver. the terms cholangiocarinoma and bile duct cancer are often used to refer to the same condition. this condition occurs slightly more often in males than females and usually affects people who are between 50-70 years old. signs and symptoms of intrahepatic cholangiocarcinoma include jaundice, abdominal pain, fever, weight loss, weakness and itching. treatment options may include surgery to remove the bile duct and parts of the liver, chemotherapy and radiation. last updated: 4/1/2014

MalaCards based summary: Intrahepatic Cholangiocarcinoma, also known as cholangiocarcinoma, is related to colorectal cancer and sarcomatous intrahepatic cholangiocarcinoma, and has symptoms including abdominal pain, malaise and abdominal pain. An important gene associated with Intrahepatic Cholangiocarcinoma is MUC4 (Mucin 4, Cell Surface Associated), and among its related pathways are Alzheimers Disease Pathway and Extracellular vesicle-mediated signaling in recipient cells. Affiliated tissues include liver, lymph node and colon, and related mouse phenotypes are Decreased cell migration and Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance.

Related Diseases for Intrahepatic Cholangiocarcinoma

About this section

Diseases related to Intrahepatic Cholangiocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 269)
idRelated DiseaseScoreTop Affiliating Genes
1colorectal cancer28.7CDH1, CDX2, CTNNB1, EGFR, EPCAM, KRAS
2sarcomatous intrahepatic cholangiocarcinoma12.2
3mucinous intrahepatic cholangiocarcinoma12.1
4signet ring cell intrahepatic cholangiocarcinoma12.0
5pigment dispersion syndrome11.2
6cholangiocarcinoma, susceptibility to11.2
7hepatitis10.6
8hepatocellular carcinoma10.5
9maternally-inherited cardiomyopathy and hearing loss10.4MUC2, MUC4, MUC5AC
10choroid epithelioid cell melanoma10.4CDX2, MUC2, MUC5AC
11thymus mucoepidermoid carcinoma10.4MUC1, MUC4, MUC5AC
12myopathy, lactic acidosis, and sideroblastic anemia 210.4MUC1, MUC2, MUC5AC
13osteosarcoma arising in bone paget's disease10.4KRT19, KRT7, MUC5AC
14breast adenocarcinoma10.4KRT19, KRT7, MUC5AC
15linitis plastica10.4CDH1, TP53
16secondary corneal edema10.4KRT19, MUC5AC, TP53
17precursor t-lymphoblastic lymphoma/leukemia10.3EGFR, KRAS, MUC1
18fibular collateral ligament bursitis10.3MUC1, MUC2, MUC4, MUC5AC
19eccrine papillary adenoma10.3AFP, KRT19, KRT7
20exudative glomerulonephritis10.3EGFR, KRAS, TP53
21refractory plasma cell neoplasm10.3MUC1, MUC2, MUC4, MUC5AC
22brachydactyly, type b110.3MUC1, MUC2, MUC4, MUC5AC
23anal carcinoma in situ10.3KRT19, KRT7, TP53
24inhibited male orgasm10.3AFP, KRAS, TP53
25ossifying fibromyxoid tumor10.3KRAS, KRT19, TP53
26paternal uniparental disomy of chromosome 110.3EGFR, IDH1, TP53
27acute eustachian salpingitis10.3CDH1, CDX2, MUC2
28hepatitis b10.3
29wolffian adnexal neoplasm10.3EGFR, TP53
30optic disk drusen10.3IDH1, IDH2
31papilloma10.3CTNNB1, MUC1, MUC4
32lymphedema10.3KRT19, MUC1, MUC4, MUC5AC
33clitoris cancer10.3CDX2, KRT20, MUC1
34cervix endometriosis10.3CDX2, KRT20, MUC2
35nasal cavity adenocarcinoma10.3KRT7, MUC1, MUC4
36childhood embryonal testis carcinoma10.3EGFR, IDH1, TP53
37testicular trophoblastic tumor10.3AFP, KRAS, MUC5AC
38lung combined type small cell carcinoma10.3KRT19, KRT7, MUC1
39testis refractory cancer10.3IDH1, IDH2, TP53
40lateral sinus thrombosis10.3CDX2, KRT19, MUC2, MUC5AC
41gastrointestinal system cancer10.3CDH1, MUC1, MUC2
42cystinosis, nephropathic10.3IDH1, IDH2, TP53
43strabismus10.3CTNNB1, MUC2, MUC5AC
44breast ductal carcinoma10.3CTNNB1, KRAS, TP53
45arthus reaction10.3AFP, KRAS, TP53
46spastic ataxia 510.3CDX2, KRT20, TP53
47mesenchymoma10.3CDX2, KRT20, MUC1
48peritoneal benign neoplasm10.3CDX2, KRT20, KRT7
49dystonia10.3CDX2, KRT20, KRT7
50infiltrative basal cell carcinoma10.3CDH1, KRT19, KRT20

Graphical network of the top 20 diseases related to Intrahepatic Cholangiocarcinoma:



Diseases related to intrahepatic cholangiocarcinoma

Symptoms & Phenotypes for Intrahepatic Cholangiocarcinoma

About this section

UMLS symptoms related to Intrahepatic Cholangiocarcinoma:


abdominal pain, malaise

GenomeRNAi Phenotypes related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00055-A-19.9ADAM17, CTNNB1, EGFR, KRAS, MUC1
2GR00210-A9.8CTNNB1, EGFR, EPCAM, FGFR2, MUC1

MGI Mouse Phenotypes related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

41 (show all 16)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00011869.7ADAM17, CTNNB1, EGFR, FGFR2, KRAS, TP53
2MP:00053719.1ADAM17, CDX2, CTNNB1, EGFR, FGFR2, IDH2
3MP:00053898.8ADAM17, AFP, CDH1, CDX2, CTNNB1, EGFR
4MP:00030128.7CDH1, CTNNB1, EGFR, EPCAM, FGFR2, KRAS
5MP:00020068.7AFP, CDH1, CDX2, CTNNB1, EGFR, FGFR2
6MP:00028738.7ADAM17, CDH1, CDX2, CTNNB1, EGFR, FGFR2
7MP:00053808.7ADAM17, CDH1, CDX2, CTNNB1, EGFR, EPCAM
8MP:00053908.7ADAM17, CDX2, CTNNB1, EGFR, FGFR2, IDH1
9MP:00053878.3ADAM17, CDH1, CTNNB1, EGFR, EPCAM, FGFR2
10MP:00053788.2ADAM17, CDH1, CDX2, CTNNB1, EGFR, EPCAM
11MP:00107688.1ADAM17, AFP, CDH1, CDX2, CTNNB1, EGFR
12MP:00053848.1ADAM17, CDH1, CDX2, CTNNB1, EGFR, EPCAM
13MP:00053858.0ADAM17, CDH1, CDX2, CTNNB1, EGFR, EPCAM
14MP:00053817.8ADAM17, CDH1, CDX2, CTNNB1, EGFR, EPCAM
15MP:00053767.8ADAM17, AFP, CDH1, CDX2, CTNNB1, EGFR
16MP:00053797.7ADAM17, AFP, CDH1, CDX2, CTNNB1, EGFR

Drugs & Therapeutics for Intrahepatic Cholangiocarcinoma

About this section

Drugs for Intrahepatic Cholangiocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 112)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1Liver ExtractsPhase 4, Phase 3, Phase 2, Phase 14067
2HematinicsPhase 4, Phase 21684
3
Oxaliplatinapproved, investigationalPhase 3, Phase 2, Phase 1146061825-94-35310940, 9887054, 6857599, 9887054, 43805
Synonyms:
CHEMBL1201055
CID9887054
D01790
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatin (TN)
Elplat
Foloxatine
L-OHP
Oxalatoplatin
 
Oxalatoplatinum
Oxaliplatin (JAN/USAN/INN)
Oxaliplatin [Usan:Inn:Ban]
Oxaliplatino [Spanish]
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
Transplatin
oxaliplatin
oxaliplatine
oxaliplatino
oxaliplatinum
4
Capecitabineapproved, investigationalPhase 3, Phase 2, Phase 11342154361-50-960953
Synonyms:
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
154361-50-9
158798-73-3
5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine
5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine
AC1L1U83
AC1Q4KU8
Ambap154361-50-9
C110904
C12650
C15H22FN3O6
CAPE
CAPECITABINE
CHEBI:31348
CHEMBL1773
CID60953
Capecitabin
Capecitabina
Capecitabine (JAN/USAN/INN)
Capecitabine [USAN]
Capecitabinum
Capecitibine
Capiibine
Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester
Caxeta
 
D01223
DB01101
FT-0082472
HSDB 7656
LS-59070
MolPort-005-938-254
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
R-340
R340
RG-340
Ro 09-1978
Ro 09-1978/000
Ro-09-1978
Ro-09-1978/000
S1156_Selleck
UNII-6804DJ8Z9U
Xabine
Xeloda
Xeloda (TN)
Xeloda, Captabin, Capecitabine
ZINC03806413
capecitabina
capecitabine
capecitabinum
pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate
5
MelphalanapprovedPhase 2, Phase 3729148-82-34053, 460612
Synonyms:
(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid
(2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid
148-82-3
3-(P-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
3-P-(Di(2-chloroethyl)amino)-phenyl-L-alanine
3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine
3025 C.B.
3025 c.b
3223-07-2
4-(Bis(2-chloroethyl)amino)-L-phenylalanine
4-14-00-01689 (Beilstein Handbook Reference)
4-[Bis(2-chloroethyl)amino]-L-phenylalanine
4-[Bis-(2-chloroethyl)amino]-L-phenylalanine
AC1LA2OE
ALKERAN (TN)
AY3360000
Alanine Nitrogen Mustard
Alkeran
AmbotzHAA1563
At-290
BIDD:GT0044
BRD-K87827419-001-02-8
BRN 2816456
BSPBio_002407
C13H18Cl2N2O2
CB 3025
CB-3025
CCRIS 374
CHEBI:165415
CHEBI:28876
CHEMBL852
CID460612
D00369
DivK1c_000653
EINECS 205-726-3
HMS2090B09
HMS2091B16
HMS502A15
HSDB 3234
IDI1_000653
KBio1_000653
KBio2_000877
KBio2_003445
KBio2_006013
KBio3_001627
KBioGR_001284
KBioSS_000877
L-3-(P-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine
L-PAM
L-Phenylalanine mustard
L-Sarcolysin
L-Sarcolysine
L-Sarkolysin
LS-15868
LS-865
 
Levofalan
Levofolan
Levopholan
M2011_SIGMA
MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN))
MLS001333666
MLS002153368
Melfalan
Melfalano
Melfalano [INN-Spanish]
Melphalan (JP15/USP/INN)
Melphalan [USAN:INN:BAN:JAN]
Melphalanum
Melphalanum [INN-Latin]
Mephalan
MolPort-003-665-535
NCGC00090757-01
NCGC00090757-02
NCGC00090757-03
NCI-C04853
NINDS_000653
NIOSH/AY3360000
NSC 241286
NSC 8806
NSC-8806
NSC241286
NSC8806
P-Di-(2-chloroethyl)amino-L-phenylalanine
P-L-Sarcolysin
P-N-Bis(2-chloroethyl)amino-L-phenylalanine
Phenylalanine mustard
Phenylalanine nitrogen mustard
Prestwick_1006
RCRA waste no. U150
Rcra waste number U150
SK-15673
SMP2_000174
SMR000058720
SPBio_000287
SPECTRUM1500382
Sarcolysine
Sarkolysin
Spectrum2_000074
Spectrum3_000684
Spectrum4_000882
Spectrum5_001601
Spectrum_000397
TL8001065
TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN)
TRANSGENIC MODEL EVALUATION (MELPHALAN)
UNII-Q41OR9510P
melphalan
p-Bis(beta-chloroethyl)aminophenylalanine
p-Di-(2-chloroethyl)amino-L-phenylalanine
p-L-Sarcolysin
p-L-sarcolysine
p-N,N-bis(2-chloroethyl)amino-L-phenylalanine
p-N-Bis(2-chloroethyl)amino-L-phenylalanine
p-N-Di(chloroethyl)aminophenylalanine
p-N-di(chloroethyl)aminophenylala nine
phenylalanine nitrogen mu stard
6
GemcitabineapprovedPhase 3, Phase 2, Phase 1201895058-81-460750
Synonyms:
103882-84-4
122111-03-9
2',2'-DiF-dC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-.beta.-D-2',2'-difluorocytidine
2'-Deoxy-2',2'-difluorocytidine
4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one
4-amino-1-((2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
95058-81-4
AB1004842
AC1L1TUQ
C07650
CCRIS 8984
CHEBI:175901
CHEMBL888
CID60750
Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine
D02368
DB00441
DDFC
DFDC
DFdC
DFdCyd
Folfugem
GEO
Gamcitabine
GemLip
Gemcel
 
Gemcin
Gemcitabin
Gemcitabina
Gemcitabina [INN-Spanish]
Gemcitabine
Gemcitabine (USAN/INN)
Gemcitabine HCl
Gemcitabine hydrochloride
Gemcitabine stereoisomer
Gemcitabinum
Gemcitabinum [INN-Latin]
Gemtro
Gemzar
Gemzar (hydrochloride)
HMS2089P10
HSDB 7567
Inno-D07001
LS-59139
LY 188011
LY-188011
LY188011
NCGC00168784-01
NChemBio.2007.10-comp25
NSC 613327
NSC613327
TL8005979
UNII-B76N6SBZ8R
ZINC18279854
Zefei
gemcitabine
nchembio.573-comp7
nchembio.90-comp2
7
CisplatinapprovedPhase 3, Phase 2, Phase 1277015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
8
CarboplatinapprovedPhase 3, Phase 2205041575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
9
SuccinylcholineapprovedPhase 3, Phase 1169306-40-15314
Synonyms:
2,2'-[(1,4-DIOXOBUTANE-1,4-DIYL)BIS(OXY)]BIS(N,N,N-TRIMETHYLETHANAMINIUM)
2,2'-[(1,4-DIOXOBUTANE-1,4-diyl)bis(oxy)]bis(N,N,N-trimethylethanaminium)
2ha2
2ha6
306-40-1
4-04-00-01451 (Beilstein Handbook Reference)
541-19-5 (diiodide)
55-94-7 (dibromide)
71-27-2 (dichloride)
AC1L1K2T
Anectine
BRN 1805311
C07546
C14H30N2O4
CHEBI:45652
CHEMBL703
CID5314
Choline, succinate (2:1) (ester)
Choline, succinate (ester)
DB00202
Diacetylcholine
Dicholine succinate
Ditilin
Ditiline
HMS2090P14
HSDB 3254
InChI=1/C14H30N2O4/c1-15(2,3)9-11-19-13(17)7-8-14(18)20-12-10-16(4,5)6/h7-12H2,1-6H3/q+2
L000926
LS-53328
Listenon
 
Lopac-S-8251
Lopac0_001080
Lysthenon
MolPort-002-964-486
NCGC00015971-01
NCGC00015971-03
NCGC00162336-01
Quelicin
Quelicin Preservative Free
SCK
ST50437287
STK177290
Scoline
Succicuran
Succinic acid, diester with choline
Succinic acid, diester with choline chloride
Succinocholine
Succinoylcholine
Succinyl choline
Succinylbischoline
Succinylcholine
Succinylcholine Chloride
Succinyldicholine
Sucostrin
Suxamethonium
Suxamethonium chloride
UNII-J2R869A8YF
ZINC01530820
succinylcholine
succinyldicholine
trimethyl-[2-[4-oxo-4-(2-trimethylazaniumylethoxy)butanoyl]oxyethyl]azanium diio
trimethyl-[2-[4-oxo-4-[2-(trimethylazaniumyl)ethoxy]butanoyl]oxyethyl]azanium
10Antineoplastic Agents, AlkylatingPhase 2, Phase 34603
11Alkylating AgentsPhase 2, Phase 34827
12Antiviral AgentsPhase 3, Phase 2, Phase 19967
13Antimetabolites, AntineoplasticPhase 3, Phase 2, Phase 17361
14Anti-Infective AgentsPhase 3, Phase 2, Phase 122062
15Immunosuppressive AgentsPhase 3, Phase 2, Phase 113086
16AntimetabolitesPhase 3, Phase 2, Phase 112054
17Peripheral Nervous System AgentsPhase 3, Phase 2, Phase 123689
18Neuromuscular AgentsPhase 3, Phase 11180
19Neuromuscular Blocking AgentsPhase 3, Phase 1429
20Neuromuscular Depolarizing AgentsPhase 3, Phase 1139
21
FluorouracilapprovedPhase 2185651-21-83385
Synonyms:
1-fluoro-1h-pyrimidine-2,4-dione
1004-03-1
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 FU Lederle
5 FU medac
5 Fluorouracil
5 Fluorouracil biosyn
5 HU Hexal
5-FU
5-FU (TN)
5-FU Lederle
5-FU medac
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5-HU Hexal
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-fluoropyrimidine-2,4(1H,3H)-dione
5-fluorouracil
51-21-8
5FU
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AI3-25297
AKOS000119162
AKOS003237897
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
BSPBio_002048
C07649
C4H3FN2O2
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
CPD0-1327
CPD000038082
CSP Brand of Fluorouracil
Carac
Carac (TN)
Carzonal
Cinco FU
Cytosafe
D005472
D00584
DB00544
Dakota Brand of Fluorouracil
Dakota, Fluorouracile
Dermatech Brand of Fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
EINECS 200-085-6
EU-0100536
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
FT-0082524
FU
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
Fluoro Uracile ICN
Fluoro-Uracile ICN
Fluoro-uracile
Fluoro-uracilo
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil GRY
Fluorouracil Mononitrate
Fluorouracil Monopotassium Salt
Fluorouracil Monosodium Salt
Fluorouracil Potassium Salt
Fluorouracil Teva Brand
Fluorouracil [USAN:INN:BAN:JAN]
 
Fluorouracil-GRY
Fluorouracile
Fluorouracile Dakota
Fluorouracile [DCIT]
Fluorouracilo
Fluorouracilo Ferrer Far
Fluorouracilo [INN-Spanish]
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
Ftoruracil
Gry Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
Haemato Brand of Fluorouracil
Haemato fu
Haemato-fu
Hexal Brand of Fluorouracil
I07-0022
ICN Brand of Fluorouracil
IDI1_000054
IN1335
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
LS-153
Lopac-F-6627
Lopac0_000536
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
NCI60_001652
NINDS_000054
NSC 19893
NSC-19893
NSC19893
Neocorp Brand of Fluorouracil
Neofluor
Onkofluor
Onkoworks Brand of Fluorouracil
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
SPECTRUM1500305
STK297802
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
Spectrum_000841
T5233394
TL8006093
Teva Brand of Fluorouracil
Timazin
U 8953
U-8953
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
Ulup
WLN: T6MVMVJ EF
ZINC00897110
biosyn Brand of Fluorouracil
fluorouracil
inhibits thymilidate synthetase
medac Brand of Fluorouracil
nchembio.90-comp3
nchembio809-comp6
ribosepharm Brand of Fluorouracil
tetratogen
22
CetuximabapprovedPhase 2752205923-56-456842117, 2333
Synonyms:
205923-56-4
Anti EGFR
Cetuximab
Cetuximab (USAN/INN)
Cetuximab (genetical recombination)
Cetuximab (genetical recombination) (JAN)
 
Cetuximabum
Cétuximab
D03455
Erbitux
Erbitux (TN)
IMC-C225
Immunoglobulin G 1 (human-mouse monoclonal C 225 gamma 1 - chain anti-human epidermal growt factor receptor), disulfide wit human-mouse monoclonal C 225 kappa - chain, dimer
cetuximab
23
Pemetrexedapproved, investigationalPhase 1, Phase 2636150399-23-8, 137281-23-3446556, 60843
Synonyms:
(2R)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid
(2S)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid
137281-23-3
150399-23-8
1juj
2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid
2-{4-[2-(2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3-D]PYRIMIDIN-5-YL)-ETHYL]-BENZOYLAMINO}-PENTANEDIOIC ACID
AC1L1U1D
AC1L2PDW
AC1L98DY
AC1L9JT6
AC1OCF51
AC1Q5R1W
Alimta
Alimta (TN)
Bio-0078
C20H19N5O6.2Na
C20H21N5O6
CHEBI:195145
CHEBI:43746
CHEBI:474008
CHEMBL1200373
CHEMBL225072
CHEMBL59843
CID125891
CID394493
CID446556
CID60843
CID6918197
D03828
D07472
DB00642
Disodium N-(p-(2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)-L-glutamate
 
HSDB 7316
I06-1253
I06-1294
I06-2128
L-Glutamic acid, N-(4-(2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)-, disodium salt
LS-172988
LS-173384
LY 231,514
LY 231514
LY-231,514
LY-2315
LY-231514
LY231514
LY231514 disodium
LYA
N-(4-(2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-d)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid
NCGC00167517-01
NCI60_035021
NSC698037
Pemetrexed
Pemetrexed (INN)
Pemetrexed Disodium
Pemetrexed [INN:BAN]
Pemetrexed disodium
Pemetrexed disodium (USAN)
Pemetrexed disodium [USAN]
Rolazar
ST51053024
Tifolar
UNII-04Q9AIZ7NO
UNII-2PKU919BA9
disodium (2R)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate
disodium (2S)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate
n-{4-[2-(2-amino-4-oxo-4,7-dihydro-1h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-d-glutamic acid
nchembio.108-comp6
24
FloxuridineapprovedPhase 2, Phase 14950-91-95790
Synonyms:
1-(2-Deoxy-beta-D-ribofuranosyl)-5-fluorouracil
1-beta-D-2'-Deoxyribofuranosyl-5-flurouracil
1beta-D-2'-Deoxyribofuranosyl-5-flurouracil
2'-Deoxy-5-fluorouridine
5 Fluorodeoxyuridine
5-FUDR
5-Fluoro-2-desoxyuridine
5-Fluorodeoxyuridine
5-Fluorouracil 2'-deoxyriboside
5-Fluorouracil deoxyriboside
5FDU
Deoxyfluorouridine
 
FDUR
FDURD
FUDR
FdU
Floxiridina
Floxiridina [INN-Spanish]
Floxuridin
Floxuridine
Floxuridinum
Floxuridinum [INN-Latin]
Fluorodeoxyuridine
Fluoruridine Deoxyribose
WR-138720
beta-5-Fluoro-2'-deoxyuridine
25
Dexamethasoneapproved, investigational, vet_approvedPhase 2, Phase 1217150-02-25743
Synonyms:
(3H)-Dexamethasone
.delta.(sup 1)-9-.alpha.-Fluoro-16-.alpha.-methylcortisol
.gamma.corten
1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone
1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
1-Dehydro-16α-methyl-9α-fluorohydrocortisone
137098-19-2
16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone
16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone
16-alpha-Methyl-9-alpha-fluoroprednisolone
16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol
16.alpha.-Methyl-9.alpha.-fluoroprednisolone
16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol
16alpha -Methyl-9alpha -fluoroprednisolone
16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone
16alpha-Methyl-9alpha-fluoroprednisolone
16α-Methyl-9α-fluoro-1-dehydrocortisol
23495-06-9
31375_FLUKA
46165_FLUKA
46165_RIEDEL
50-02-2
8054-59-9
9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione
9-Fluoro-16-methylprednisolone
9-alpha-Fluoro-16-alpha-methylprednisolone
9.alpha.-Fluoro-16.alpha.-methylprednisolone
906422-84-2
9A-FLUORO-16BETA-METHYLPREDNISOLONE
9alpha -Fluoro-16alpha -methylprednisolone
9alpha-Fluoro-16alpha-methylprednisolone
9alpha-fluoro-16alpha-methyl-Prednisolone
9α-Fluoro-16α-methylprednisolone
AC-11056
AC1L1L1H
AC1Q29DM
AI3-50934
Adexone
Aeroseb-D
Aeroseb-Dex
Aeroseb-dex
Ak Dex Oph Otic Soln 0.1%
Alcon Brand of Dexamethasone
Anaflogistico
Aphtasolon
Aphthasolone
Apo-dexamethasone
Auxiron
Azimycin (veterinary)
Azium
Azium (Veterinary)
Azium (veterinary)
BIDD:ER0494
BIDD:PXR0060
BRD-K38775274-001-02-3
BRD-K38775274-001-06-4
BSPBio_000995
Bisu DS
Bisu Ds
C15643
C22H29FO5
CCRIS 7067
CHEBI:41879
CHEMBL384467
CID5743
CPD-10549
CPD001227192
Calonat
Corson
Corsone
Cortisumman
D00292
D003907
D1756_SIGMA
D4902_SIGMA
D6645_SIGMA
D8893_SIGMA
D9184_SIGMA
DB01234
DEX
DEXA
DEXONE 0.5
DEXONE 0.75
DEXONE 1.5
DEXONE 4
DXM
DXMS
Decacort
Decacortin
Decaderm
Decadron
Decadron (TN)
Decadron Tablets, Elixir
Decadron, Dexamethasone
Decadron-LA
Decadron-La
Decagel
Decaject
Decaject L.A.
Decaject-L.A.
Decalix
Decameth
Decasone
Decaspray
Dectancyl
Dekacort
Delta1-9alpha-Fluoro-16alpha-methylcortisol
Deltafluorene
Dergramin
Deronil
Desadrene
Desametasone
Desametasone [DCIT]
Desametasone [Dcit]
Desamethasone
Desameton
Deseronil
Dex-Ide
Dex-ide
Dexa
Dexa Mamallet
Dexa mamallet
Dexa-Cortidelt
Dexa-Cortisyl
Dexa-Mamallet
Dexa-Scheroson
Dexa-Sine
Dexa-cortidelt
Dexa-cortisyl
Dexa-scheroson
Dexa-sine
Dexacen-4
Dexacidin
Dexacort
Dexacortal
Dexacortin
Dexadeltone
Dexafarma
Dexair
Dexalona
Dexaltin
Dexametasona
Dexametasona [INN-Spanish]
Dexametasone
 
Dexameth
Dexamethansone
Dexamethasone
Dexamethasone (JP15/USP/INN)
Dexamethasone Acetate
Dexamethasone Alcohol
Dexamethasone Base
Dexamethasone Intensol
Dexamethasone Sodium Phosphate
Dexamethasone [INN:BAN:JAN]
Dexamethasone alcohol
Dexamethasone base
Dexamethasone intensol
Dexamethasone-omega
Dexamethasonum
Dexamethasonum [INN-Latin]
Dexamethazone
Dexamonozon
Dexapolcort
Dexapos
Dexaprol
Dexason
Dexasone
Dexasone 0.5mg
Dexasone 0.75mg
Dexasone 4mg
Dexasporin
Dexinolon
Dexinoral
Dexone
Dexone 0.5
Dexone 0.75
Dexone 1.5
Dexone 4
Dexonium
Dexpak
Dextelan
Dezone
Dinormon
Dxms
ECR Brand of Dexamethasone
EINECS 200-003-9
FT-0080377
Fluormethylprednisolone
Fluormone
Fluorocort
Fortecortin
Foy Brand of Dexamethasone
Gammacorten
HL-dex
HMS1792A17
HMS1990A17
HMS2089N13
HSDB 3053
Hexadecadrol
Hexadrol
Hexadrol Elixir
Hexadrol Tablets
Hexadrol elixir
Hl-Dex
Hl-dex
I06-1196
ICN Brand of Dexamethasone
IontoDex
Isopto-Dex
Isopto-dex
LS-7300
Lokalison F
Lokalison f
Loverine
Luxazone
MK 125
MLS001055412
MLS001332507
MLS001332508
Maxidex
Maxidex Ont 0.1%
Maxidex Sus 0.1%
Maxitrol
Mediamethasone
Merck Brand of Dexamethasone
Merz Brand 1 of Dexamethasone
Merz Brand 2 of Dexamethasone
Methylfluorprednisolone
Mexidex
Millicorten
MolMap_000018
MolPort-003-846-433
Mymethasone
NCGC00091019-01
NCGC00091019-02
NCGC00091019-03
NCGC00091019-04
NCGC00091019-05
NCI60_003067
NSC 34521
NSC34521
Naquasone (veterinary)
Neomycin and polymyxin b sulfates and dexamethasone
Neomycin and polymyxin b sulphates and dexamethasone
OTO-104
Ocu-Trol
Ocu-trol
Oradexon
PHL-dexamethasone
PMS-dexamethasone
Pet Derm III
Pet Derm Iii
Pet derm III
Pet-Derm Iii
Pms Dexamethasone Elixir 0.5mg/5ml
Policort
Posurdex
Prednisolon F
Prednisolon f
Prednisolone F
Prednisolone f
Prodex
S1322_Selleck
SAM002548948
SGCUT00126
SK-Dexamethasone
SK-dexamethasone
SMP1_000092
SMR000857119
SMR001227192
ST50307091
Sandoz dexamethasone
Sk-Dexamethasone
Spectrum5_002019
Spoloven
Sunia Sol D
Sunia sol D
Superprednol
TL8003317
Tobradex
Tobramycin and dexamethasone
Tresaderm (veterinary)
Turbinaire
UNII-7S5I7G3JQL
Visumetazone
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ G1
ZINC03875332
alpha -Fluoro-16-alpha -methylcortisol
delta(Sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta1-9alpha-Fluoro-16alpha-methylcortisol
dexamethasone
nchembio809-comp2
to_000038
26
Doxorubicinapproved, investigationalPhase 1, Phase 2175123214-92-831703
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
14-hydroxydaunomycin
14-hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
ADM
ADR
Adriablastin
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin Semiquinone
Adriamycin semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (TN)
Adriblastina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Caelyx
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
DOX-SL
Doxil
Doxo
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin HCl
 
Doxorubicin Hydrochloride
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicinum
Doxorubicinum [INN-Latin]
EINECS 245-495-6
FI 106
Farmablastina (hydrochloride salt)
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NCI-C01514
NChemBio.2007.10-comp13
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
TLC D-99
ThermoDox
Triferric doxorubicin
UNII-80168379AG
adiblastine (hydrochloride salt)
adr iablatina (hydrochloride salt)
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
adriblatina (hydrochloride salt)
doxorubicin
nchembio809-comp5
27
Irinotecanapproved, investigationalPhase 2112397682-44-5, 100286-90-660838
Synonyms:
(+)-Irinotecan
(4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE
(4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate
1u65
97682-44-5
AC-7469
AC1L1U0Z
AC1Q6PGI
BRD-K08547377-003-02-4
BSPBio_002346
Bio-0054
Biotecan
Biotecan (TN)
C16641
C33H38N4O6
CHEBI:105985
CHEMBL481
CID60838
CP0
Campothecin-11
Campto
Camptosar
 
Camptosar, Campto, CPT-11, Irinotecan
Camptothecin-11
D08086
DB00762
FT-0083650
HSDB 7607
IRINOTECAN HYDROCHLORIDE Trihydrate
IRINOTECAN, CPT-11
Irinotecan (INN)
Irinotecan Hcl
Irinotecan Hydrochloride
Irinotecan Hydrochloride Trihydrate
Irinotecan [INN:BAN]
Irinotecan hydrochloride
Irinotecanum
Irinotecanum [INN-Latin]
LS-44589
NCI60_005051
NSC728073
S1198_Selleck
TL8006026
UNII-7673326042
irinotecan
28
chloroquineapproved, vet_approvedPhase 1, Phase 214954-05-72719
Synonyms:
( -)-Chloroquine
(+)-Chloroquine
(-)-Chloroquine
(R)-(-)-Chloroquine
3377 RP opalate
3545-67-3
50-63-5
54-05-7
56598-66-4
58175-86-3
58175-87-4
7-Chloro-4-((4-(diethylamino)-1-methylbutyl)amino)quinoline
7-Chloro-4-[[4-(diethylamino)-1-methylbutyl]amino]quinoline
AB00053436
AC1L1EB8
AC1Q2ZA7
AC1Q2ZA8
Amokin
Aralen
Aralen HCl
Arechin
Arechine
Arequin
Arolen
Arthrochin
Artrichin
Avlochlor
Avloclor
BPBio1_000655
BRD-A91699651-065-01-1
BRN 0482809
BSPBio_000595
BSPBio_002001
Bemaco
Bemaphate
Bemasulph
Benaquin
Bipiquin
C07625
C18H26ClN3
CCRIS 3439
CHEBI:3638
CHEMBL76
CID2719
CQ
CU-01000012392-2
Capquin
Chemochin
Chingamin
Chloraquine
Chlorochin
Chlorochine
Chlorochinum
Chloroin
Chloroquin
Chloroquina
Chloroquine
Chloroquine (USP/INN)
Chloroquine (VAN)
Chloroquine Bis-Phosphoric Acid
Chloroquine Phosphate
Chloroquine [USAN:INN:BAN]
Chloroquine phosphate
Chloroquinium
Chloroquinum
Chloroquinum [INN-Latin]
Chlorquin
Cidanchin
Clorochina
Clorochina [DCIT]
Cloroquina
Cloroquina [INN-Spanish]
Cocartrit
D02366
DB00608
Dawaquin
Delagil
Dichinalex
DivK1c_000404
EINECS 200-191-2
Elestol
Gontochin
Gontochin phosphate
HMS2090O03
HSDB 3029
Heliopar
Hydroxychloroquine Sulfate
IDI1_000404
Imagon
 
Ipsen 225
Iroquine
KBio1_000404
KBio2_000592
KBio2_003160
KBio2_005728
KBio3_001221
KBioGR_000778
KBioSS_000592
Khingamin
Klorokin
LS-141726
Lapaquin
Lopac0_000296
Malaquin
Malaquin (*Diphosphate*)
Malaren
Malarex
Mesylith
Miniquine
MolMap_000009
MolPort-001-783-623
N(4)-(7-chloro-4-Quinolinyl)-N(1),N(1)-diethyl-1,4-pentanediamine
N4-(7-Chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine
N4-(7-chloroquinolin-4-yl)-N1,N1-diethylpentane-1,4-diamine
NCGC00015256-04
NCGC00162120-01
NCI60_000894
NINDS_000404
NSC 187208
NSC14050
NSC187208
Neochin
Nivachine
Nivaquine
Nivaquine B
Pfizerquine
Plaquenil
Prestwick0_000548
Prestwick1_000548
Prestwick2_000548
Prestwick3_000548
Quinachlor
Quinagamin
Quinagamine
Quinercyl
Quingamine
Quinilon
Quinoscan
RP 3377
RP-3377
Resochen
Resochin
Resoquina
Resoquine
Reumachlor
Reumaquin
Rivoquine
Ro 01-6014/N2
Ronaquine
Roquine
SMP2_000034
SN 6718
SN-7618
SPBio_000174
SPBio_002516
ST 21
ST 21 (pharmaceutical)
Sanoquin
Silbesan
Siragan
Solprina
Sopaquin
Spectrum2_000127
Spectrum3_000341
Spectrum4_000279
Spectrum5_000707
Spectrum_000132
Tanakan
Tanakene
Tresochin
Trochin
UNII-886U3H6UFF
W 7618
WIN 244
WLN: T66 BNJ EMY1&3N2&2 IG
chloroquine
nchembio.215-comp4
nchembio.368-comp8
nchembio.87-comp17
{4-[(7-chloroquinolin-4-yl)amino]pentyl}diethylamine
29
Ramucirumabapproved, investigationalPhase 276947687-13-0
Synonyms:
IMC-1121B
 
IMC-3G3
ramucirumab
30
CeritinibapprovedPhase 2371032900-25-6
Synonyms:
2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2- isopropylsulfonyl)phenyl) pyrimidine-2,4-diamine
LDK378
 
N-{2-[(5-chloro-2-{[2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}propane-2-sulfonamide
Zykadia
céritinib
31
MetforminapprovedPhase 1, Phase 21803657-24-914219, 4091
Synonyms:
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
3-(diaminomethylidene)-1,1-dimethylguanidine
657-24-9
AC1L1HE4
AKOS000121065
Apo-Metformin
BIDD:GT0697
BPBio1_000009
BRD-K79602928-003-04-1
BSPBio_000007
BSPBio_002314
C07151
C4H11N5
CAS-1115-70-4
CCRIS 9321
CHEBI:6801
CHEMBL1431
CID4091
D04966
DB00331
DMGG
Diabetosan
Diabex
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
EINECS 211-517-8
Fluamine
Flumamine
Fortamet
Gen-Metformin
Glifage
Gliguanid
Glucophage
Glucophage XR
Glumetza
Glycon
HMS2089D19
HSCI1_000295
Haurymelin
Haurymellin
Islotin
KBio2_002310
KBio2_004878
KBio2_007446
KBio3_002790
KBioGR_002310
 
KBioSS_002312
LA-6023
LS-43899
Melbin
Metformin
Metformin (USAN/INN)
Metformin HCL
Metformin [USAN:INN:BAN]
Metformina
Metformina [DCIT]
Metformina [Spanish]
Metformine
Metformine [INN-French]
Metformine pamoate
Metforminum
Metforminum [INN-Latin]
Metiguanide
MolPort-002-929-560
MolPort-004-288-389
MolPort-005-767-418
Mylan-Metformin
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylimidodicarbonimidic diamide
N,N-dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
NCGC00016564-01
NCGC00016564-02
NCGC00016564-03
NNDG
Novo-Metformin
Nu-Metformin
PMS-Metformin
Prestwick0_000004
Prestwick1_000004
Prestwick2_000004
Prestwick3_000004
Ran-Metformin
Ratio-Metformin
Riomet
S2483_Selleck
SPBio_001928
STK011633
Sandoz Metformin
Siofor
T5895664
Teva-Metformin
UNII-9100L32L2N
ZINC12859773
cMAP_000016
metformin
metformin hydrochloride
32
Paclitaxelapproved, vet_approvedPhase 2286433069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nab-paclitaxel
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
33
nivolumabapprovedPhase 2424946414-94-4
Synonyms:
BMS-936558
 
MDX-1106
ONO-4538
nivolumab
34
Dasatinibapproved, investigationalPhase 2285302962-49-83062316
Synonyms:
(18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
1N1
2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide
302962-49-8
AC1MI3ET
AC1Q2P0C
AmbotzLS-1203
Anhydrous dasatinib
BCB03_000715
BMS 354825
BMS dasatinib
BMS-354825
BMS-354825, Sprycel, BMS354825, Dasatinib
BMS354825
C488369
CHEBI:49375
CHEMBL1421
CID3062316
D03658
DB01254
Dasatinib
Dasatinib (USAN)
Dasatinib (anh.)
Dasatinib [USAN]
Dasatinib anhydrous
Dasatinib, BMS 354825
Dasatinibum
EC-000.2122
 
EN002710
FT-0084503
I14-1972
Kinome_3650
LS-186641
LS-187028
LS-187773
MolPort-003-846-143
N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE
N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate
N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
NCGC00181129-01
NSC-732517
NSC732517
S1021_Selleck
SPRYCEL (TN)
Sprycel
Spyrcel
UNII-X78UG0A0RN
anh. dasatinib
dasatinib
dasatinib (anhydrous)
dasatinibum
nchembio.117-comp11
nchembio.162-comp4
nchembio.332-comp1
35
Calcitriolapproved, nutraceuticalPhase 221032222-06-3134070, 5280453
Synonyms:
(1R,3S)-5-{2-[(1R,3aS,7aR)-1-((R)-5-Hydroxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-4-ylidene]-ethylidene}-4-methylene-cyclohexane-1,3-diol
(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
(1S,3R,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol
(1S,3R,5Z,7E)-9,10-secocholesta-5,7,10-triene-1,3,25-triol
(1alpha,3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol
(1α,3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol
(3b,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trienetriol
(5Z,7E)-(1S,3R)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol
(5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1-alpha,3-beta,25-triol
(5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1alpha,3beta,25-triol
1 alpha,25-Dihydroxyvitamin D3
1,25 (OH)2 D3
1,25 Dihydroxycholecalciferol
1,25(OH)2-20epi-D3
1,25(OH)2D3 & CD4
1,25(OH2)D3
1,25-(OH)2-D3
1,25-(OH)2D3
1,25-DHCC
1,25-DIHYDROXYCHOLECALCIFEROL
1,25-Dihydroxycholecalciferol
1,25-Dihydroxycholecaliferol
1,25-Dihydroxyvitamin D
1,25-Dihydroxyvitamin D3
1,25-dihydroxy vitamin D3
1,25-dihydroxy-20-epi-Vitamin D3
1,25-dihydroxycholecalciferol
1,25D3
1-alpha,-1,25-Dihydroxyvitamin D3
1-alpha,25-Dihydroxycholecalciferol
1-alpha,25-Dihydroxyvitamin D3
1-alpha-25-Dihydroxyvitamin D3
1-alpha-25-dihydroxyvitamin D3
1.Alpha.,25-Dihydroxy-26,27-hexadeuterovitamin D3
17936_FLUKA
17936_SIGMA
1a,25-(OH)2D3
1a,25-Dihydroxycholecalciferol
1a,25-Dihydroxyvitamin D3
1alpha,25(OH)2-D3
1alpha,25(OH)2D3
1alpha,25-Dihydroxycholecalciferol
1alpha,25-Dihydroxyvitamin D
1alpha,25-Dihydroxyvitamin D3
1db1
1α,25(OH)2D3
1α,25-dihydroxycholecalciferol
1α,25-dihydroxyvitamin D3
20-epi-1alpha,25-dihydroxycholecaliferol
25-Dihydroxycholecalciferol
32222-06-3
9,10-Seco(5Z,7E)-5,7,10(19)-cholestatriene-1alpha,3beta,25-triol
9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol, (1.alpha.,3.beta,.5Z,7E)- & CD4
9,10-seco(5Z,7E)-5,7,10(19)-cholestatriene-1alpha, 3beta, 25-triol
AC-1859
AC1NQX1S
Ambap32222-06-3
 
Asentar
BCBcMAP01_000160
BML2-E03
BSPBio_001287
C01673
CCRIS 5522
CD-2027
CHEBI:17823
CHEMBL846
CID5280453
CPD000466393
Calcijex
Calcijex, Silkis, Rocaltrol, Topitriol, Cholecalciferol,Calcitriol
Calcitriol
Calcitriol (JAN/USAN/INN)
Calcitriol [USAN:INN:BAN:JAN]
Calcitriolum
Calcitriolum [INN-Latin]
D00129
D1530_SIGMA
DN 101
DN-101
Decostriol
Dihydroxyvitamin D3
EINECS 250-963-8
HMS1361A09
HMS1791A09
HMS1989A09
HMS2051F06
HMS2089N03
HSDB 3482
IDI1_033757
LMST03020258
LS-53093
MC-1288
MC1288
MLS000759536
MLS001424122
MolPort-002-045-698
NCGC00161327-01
NCGC00161327-04
Ro 21-5535
Ro 215535
Ro-21-5535
Rocaltrol
Rocaltrol (TN)
S1466_Selleck
SAM001246772
SMR000466393
Silkis
Soltriol
Spectrum5_002061
Topitriol
Toptriol
U 49562
Vectical
ZINC03924790
calcitriol
vit D
36
leucovorinapproved, NutraceuticalPhase 2, Phase 1323558-05-954575, 6560146, 143
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R,S)-5-Formyltetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-Formyltetrahydrofolate
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
5-formyltetrahydrofolic acid
Acide folinique
Calcium citrovorum factor
Calcium folinate
Citrovorum factor
Folinate
Folinic acid
Folinic acid calcium salt
 
Folinic acid calcium salt USP27
Folinic acid-SF
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
L-Leucovorin
L-N-[p-[[(2-Amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-Glutamic acid
L-leucovorin
Leucal
Leucovorin calcium
Leucovorin folinic acid
Leucovorinum
Leukovorin
Levoleucovorin
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyl-THF
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
Welcovorin
Wellcovorin
folinate
37
Folic Acidapproved, nutraceutical, vet_approvedPhase 1, Phase 2439259-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
Folsaeure
 
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
38
DoxilApproved June 1999Phase 1, Phase 2175131703
Synonyms:
Dox-SL
Doxil
 
Evacet
LipoDox
Pegylated Liposomal Doxorubicin Hydrochloride
liposomal doxorubicin
39Trace ElementsPhase 26001
40Antibiotics, AntitubercularPhase 2, Phase 17180
41Anti-Bacterial AgentsPhase 2, Phase 111226
42VitaminsPhase 25282
43Vasoconstrictor AgentsPhase 22122
44Bone Density Conservation AgentsPhase 23376
45Nucleic Acid Synthesis InhibitorsPhase 2, Phase 14962
46vitamin dPhase 21724
47MitomycinsPhase 2240
48Calcium, DietaryPhase 25713
49MicronutrientsPhase 26001
50Vitamin B ComplexPhase 1, Phase 24337

Interventional clinical trials:

(show top 50)    (show all 71)
idNameStatusNCT IDPhase
1Stereotactic Body Radiotherapy for Liver TumorsActive, not recruitingNCT01347333Phase 4
2Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by SurgeryCompletedNCT01313377Phase 3
3Oxaliplatin+Gemcitabine vs Capecitabine as Adjuvant Therapy for Intrahepatic CholangiocarcinomaRecruitingNCT02548195Phase 3
4Study of GEMOX(Gemcitabine/Oxaliplatin) Versus XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract CarcinomaRecruitingNCT01470443Phase 3
5Gemcitabine Hydrochloride and Cisplatin With or Without Radiation Therapy in Treating Patients With Localized Liver Cancer That Cannot Be Removed by SurgeryActive, not recruitingNCT02200042Phase 3
6A Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Patients With Resected or Ablation Intra-Hepatic CholangiocarcinomaNot yet recruitingNCT03081039Phase 3
7Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic CholangiocarcinomaNot yet recruitingNCT03086993Phase 2, Phase 3
8Calcitriol in Advanced Intrahepatic CholangiocarcinomaUnknown statusNCT01039181Phase 2
9Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic CholangiocarcinomaUnknown statusNCT02415036Phase 2
10Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From CholangiocarcinomaUnknown statusNCT01247337Phase 2
11Regorafenib Versus Placebo to Treat CholangiocarcinomaUnknown statusNCT02162914Phase 2
12Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract CancerCompletedNCT00753675Phase 2
13Cabozantinib (XL-184) Monotherapy for Advanced CholangiocarcinomaCompletedNCT01954745Phase 2
14Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell LympCompletedNCT02273739Phase 1, Phase 2
15A Phase II Study of Continuous Hepatic Arterial Infusion With Floxuridine (FUDR) and Dexamethasone (DEX) in Patients With Unresectable Primary Hepatic MalignancyCompletedNCT00587067Phase 2
16Downsizing of Unresectable Cholangiocarcinoma by Combined Intravenous and Intra-arterial ChemotherapyCompletedNCT01692704Phase 1, Phase 2
17Oxaliplatin and Capecitabine in Patients With Unresectable CholangiocarcinomaCompletedNCT00338988Phase 2
18Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the LiverCompletedNCT00041808Phase 1, Phase 2
19Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder CancerCompletedNCT00059865Phase 1, Phase 2
20DX-8951f in Treating Patients With Biliary CancerCompletedNCT00005938Phase 2
21Panitumumab Plus Gemcitabine and Oxaliplatin (GEMOX)Versus GEMOX Alone to Treat Advanced Biliary Tract AdenocarcinomaCompletedNCT01389414Phase 2
22Drug-Eluting Bead, Irinotecan Therapy for Unresectable Intrahepatic Cholangiocarcinoma w/Concomitant Gemcitabine and Cisplatin or CarboplatinRecruitingNCT01648023Phase 2
23Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)RecruitingNCT01862315Phase 2
24Treatment for Bile Duct Cancer in the LiverRecruitingNCT02167711Phase 2
25Metformin And Chloroquine in IDH1/2-mutated Solid TumorsRecruitingNCT02496741Phase 1, Phase 2
26Nivolumab and Ipilimumab in Treating Patients With Rare TumorsRecruitingNCT02834013Phase 2
27Gemcitabine, Cisplatin, and Abraxane in Advanced Biliary CancersRecruitingNCT02392637Phase 2
28Ramucirumab for Advanced Pre-treated Biliary CancersRecruitingNCT02520141Phase 2
29A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar CholangiocarcinomaRecruitingNCT02374489Phase 2
30Selective Internal Radiotherapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Cholangiocellular Carcinoma (CCC).RecruitingNCT01798147Phase 2
31Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced CholangiocarcinomaRecruitingNCT02631590Phase 2
32Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic CholangiocarcinomaActive, not recruitingNCT02428855Phase 2
33Efficacy Study of Intra-hepatic Administration of Therasphere® in Association With Intravenous Chemotherapy to Treat CholangiocarcinomaActive, not recruitingNCT01912053Phase 2
34Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic AlterationsActive, not recruitingNCT01752920Phase 1, Phase 2
35Liver Transplantation for Early Intrahepatic CholangiocarcinomaNot yet recruitingNCT02878473Phase 2
36A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients With Advanced Intra-Hepatic CholangiocarcinomaNot yet recruitingNCT02994251Phase 2
37Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract CancerNot yet recruitingNCT03044587Phase 2
38A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare CancersNot yet recruitingNCT02923934Phase 2
39Study of Low-Dose Radiation Therapy to the Whole Liver in Combination With Gemcitabine and Cisplatin in Intrahepatic CholangiocarcinomaTerminatedNCT02254681Phase 2
40Second-line Therapy of Unresectable Cholangiocarcinoma by RADIOEMBOLIZATIONTerminatedNCT01383746Phase 1, Phase 2
41Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder CancerTerminatedNCT00386516Phase 2
42Response of Hepatic Tumors to RadioembolizationWithdrawnNCT01775280Phase 2
43Stereotactic Body Radiotherapy for Hepatocellular Carcinoma, and Intrahepatic CholangiocarcinomaCompletedNCT01668134Phase 1
44Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic CholangiocarcinomaRecruitingNCT01525069Phase 1
45Phase I Study of BAY1436032 in Isocitrate Dehydrogenase-1 (IDH1)-Mutant Advanced Solid TumorsRecruitingNCT02746081Phase 1
46Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or GallbladderRecruitingNCT02375880Phase 1
47Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic CholangiocarcinomaActive, not recruitingNCT01938729Phase 1
48Yttrium Y 90 Glass Microspheres and Capecitabine in Treating Patients With Liver Cholangiocarcinoma or Liver MetastasesActive, not recruitingNCT00858429Phase 1
49Tremelimumab With Chemoembolization or Ablation for Liver CancerActive, not recruitingNCT01853618Phase 1
50Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by SurgeryWithdrawnNCT03117855Phase 1

Search NIH Clinical Center for Intrahepatic Cholangiocarcinoma


Cochrane evidence based reviews: cholangiocarcinoma

Genetic Tests for Intrahepatic Cholangiocarcinoma

About this section

Anatomical Context for Intrahepatic Cholangiocarcinoma

About this section

MalaCards organs/tissues related to Intrahepatic Cholangiocarcinoma:

36
Liver, Lymph node, Colon, Skeletal muscle, Endothelial, T cells, Kidney

Publications for Intrahepatic Cholangiocarcinoma

About this section

Articles related to Intrahepatic Cholangiocarcinoma:

(show top 50)    (show all 713)
idTitleAuthorsYear
1
Loss of Secreted Frizzled-Related Protein-1 expression is associated with poor prognosis in intrahepatic cholangiocarcinoma. (28062160)
2017
2
Gene alterations and epigenetic changes in intrahepatic cholangiocarcinoma. (27893290)
2017
3
The role of interventional radiology in the treatment of intrahepatic cholangiocarcinoma. (28008570)
2017
4
A significant cancer burden and high mortality of intrahepatic cholangiocarcinoma in Thailand: a nationwide database study. (28056836)
2017
5
Corrigendum: A novel mouse model of intrahepatic cholangiocarcinoma induced by liver-specific Kras activation and Pten deletion. (28045050)
2017
6
The risk factors and prognostic factors of intrahepatic cholangiocarcinoma. (28089545)
2017
7
Albumin to gamma-glutamyltransferase ratio as a prognostic indicator in intrahepatic cholangiocarcinoma after curative resection. (28076328)
2017
8
Expression and prognostic value of soluble CD97 and its ligand CD55 in intrahepatic cholangiocarcinoma. (28345461)
2017
9
TAZ regulates cell proliferation and sensitivity to vitamin D3 in intrahepatic cholangiocarcinoma. (27554639)
2016
10
Mass-forming intrahepatic cholangiocarcinoma: Enhancement patterns in the arterial phase of dynamic hepatic CT - Correlation with clinicopathological findings. (27165138)
2016
11
Mass-forming Intrahepatic Cholangiocarcinoma: Diffusion-weighted Imaging as a Preoperative Prognostic Marker. (27115053)
2016
12
Recurrent Cardiac Tamponade: An Unusual Presentation of Intrahepatic Cholangiocarcinoma. (27144206)
2016
13
Two classes of intrahepatic cholangiocarcinoma defined by relative abundance of mutations and copy number alterations. (27009864)
2016
14
Genetic profiling of intrahepatic cholangiocarcinoma and its clinical implication in targeted therapy. (27152236)
2016
15
Impact of Skeletal Muscle Mass, Muscle Quality, and Visceral Adiposity on Outcomes Following Resection of Intrahepatic Cholangiocarcinoma. (27837297)
2016
16
Intrahepatic Cholangiocarcinoma in the Liver Explant After Liver Transplantation: Histological Differentiation and Prognosis. (27068242)
2016
17
Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation. (26868125)
2016
18
Defining when to offer operative treatment for intrahepatic cholangiocarcinoma: A regret-based decision curves analysis. (27046702)
2016
19
TLR2 promotes human intrahepatic cholangiocarcinoma cell migration and invasion by modulating NF-I_B pathway-mediated inflammatory responses. (27616304)
2016
20
Is Radiotherapy Warranted Following Intrahepatic Cholangiocarcinoma Resection? The Impact of Surgical Margins and Lymph Node Status on Survival. (27654107)
2016
21
Liver transplantation for "very early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment. (27481548)
2016
22
Down-Regulation of Nogo-B Expression as a Newly Identified Feature of Intrahepatic Cholangiocarcinoma. (26656426)
2016
23
Intrahepatic cholangiocarcinoma coinciding with a liver metastasis from a rectal carcinoma: a case report. (27612869)
2016
24
Double primary hepatic cancer (hepatocellular carcinoma and intrahepatic cholangiocarcinoma) originating from hepatic progenitor cell: a case report and review of the literature. (27535234)
2016
25
Intrahepatic cholangiocarcinoma and perihilar cholangiocarcinoma -differentiation in terms of imaging diagnoses and surgical procedures. (27593364)
2016
26
Intrahepatic cholangiocarcinoma in a patient with Wilson's disease: a case report. (27005296)
2016
27
Molecular Pathogenesis and Current Therapy in Intrahepatic Cholangiocarcinoma. (27170400)
2016
28
Local therapy reduces the risk of liver failure and improves survival in patients with intrahepatic cholangiocarcinoma: A comprehensive analysis of 362 consecutive patients. (27984655)
2016
29
Members of the Cyr61/CTGF/NOV Protein Family: Emerging Players in Hepatic Progenitor Cell Activation and Intrahepatic Cholangiocarcinoma. (27829832)
2016
30
ZEB1 expression is associated with prognosis of intrahepatic cholangiocarcinoma. (26670746)
2016
31
STAT3 overexpression promotes metastasis in intrahepatic cholangiocarcinoma and correlates negatively with surgical outcome. (28032598)
2016
32
Clinicopathological differences between intrahepatic cholangiocarcinoma and hilar cholangiocarcinoma. (27593363)
2016
33
Extracellular vesicles carry microRNA-195 to intrahepatic cholangiocarcinoma and improve survival in a rat model. (27474881)
2016
34
The differences between intrahepatic cholangiocarcinoma and hilar cholangiocarcinoma -from diagnosis and biliary drainage points of view. (27593362)
2016
35
Paraneoplastic fibrillary glomerulonephritis associated with intrahepatic cholangiocarcinoma: When diagnosis of a rare kidney disease leads to successful hepatic cancer treatment. (27542513)
2016
36
EYA4 gene functions as a prognostic marker and inhibits the growth of intrahepatic cholangiocarcinoma. (27469137)
2016
37
Differentiation of mass-forming intrahepatic cholangiocarcinoma from poorly differentiated hepatocellular carcinoma: based on the multivariate analysis of contrast-enhanced computed tomography findings. (27193795)
2016
38
A novel mouse model of intrahepatic cholangiocarcinoma induced by liver-specific Kras activation and Pten deletion. (27032374)
2016
39
Outcomes for Patients with Recurrent Intrahepatic Cholangiocarcinoma After Surgery. (27581609)
2016
40
Depletion of STYK1 inhibits intrahepatic cholangiocarcinoma development both in vitro and in vivo. (27542675)
2016
41
Synchronous pancreatic adenocarcinoma and intrahepatic cholangiocarcinoma arising in the context of intraductal papillary neoplasms. (27183137)
2016
42
Small Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in Cirrhotic Livers May Share Similar Enhancement Patterns at Multiphase Dynamic MR Imaging. (27077381)
2016
43
Immunohistochemistry Using Monoclonal Antibody MsMab-2 Is Useful to Detect IDH1 R132L in Intrahepatic Cholangiocarcinoma. (27595804)
2016
44
Loss of BAP1 Expression Occurs Frequently in Intrahepatic Cholangiocarcinoma. (26765459)
2016
45
The favorable prognosis after operative resection of hypervascular intrahepatic cholangiocarcinoma: A clinicopathologic and immunohistochemical study. (27155908)
2016
46
Low Incidence of Lymph Node Metastasis After Resection of Hepatitis Virus-Related Intrahepatic Cholangiocarcinoma. (27896410)
2016
47
Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma. (27012989)
2016
48
Overexpression of PDZK1IP1, EEF1A2 and RPL41 genes in intrahepatic cholangiocarcinoma. (27082702)
2016
49
The association between non-alcoholic steatohepatitis and intrahepatic cholangiocarcinoma: A hospital based case-control study. (26996383)
2016
50
Low expression of ARID1A correlates with poor prognosis in intrahepatic cholangiocarcinoma. (27433094)
2016

Variations for Intrahepatic Cholangiocarcinoma

About this section

Expression for genes affiliated with Intrahepatic Cholangiocarcinoma

About this section
Search GEO for disease gene expression data for Intrahepatic Cholangiocarcinoma.

Pathways for genes affiliated with Intrahepatic Cholangiocarcinoma

About this section

Pathways related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

(show all 30)
idSuper pathwaysScoreTop Affiliating Genes
19.8ADAM17, EGFR, FGFR2
29.8CTNNB1, EGFR, KRAS
39.8CTNNB1, EGFR, TP53
49.8CDH1, CTNNB1, EGFR
59.8CDH1, CTNNB1, EGFR
6
Show member pathways
9.7MUC1, MUC2, MUC4, MUC5AC
7
Show member pathways
9.7MUC1, MUC2, MUC4, MUC5AC
8
Show member pathways
9.7MUC1, MUC2, MUC4, MUC5AC
9
Show member pathways
9.7CDH1, EGFR, KRAS, TP53
109.7CDH1, CTNNB1, KRAS, TP53
11
Show member pathways
9.7EGFR, FGFR2, KRAS, TP53
129.7ADAM17, AFP, CDX2, CTNNB1
139.7CDH1, CTNNB1, EPCAM, MUC1
149.6CTNNB1, EGFR, KRAS, TP53
159.6CTNNB1, EGFR, KRAS, TP53
169.6AFP, CDX2, EPCAM, KRT19
17
Show member pathways
9.6KRAS, MUC1, MUC2, MUC4, MUC5AC
189.5EGFR, FGFR2, IDH1, KRAS, TP53
199.4CDH1, CTNNB1, EGFR, KRAS, TP53
20
Show member pathways
9.4CDH1, CTNNB1, EGFR, KRAS, TP53
21
Show member pathways
9.4CTNNB1, EGFR, FGFR2, KRAS, TP53
22
Show member pathways
9.4CDH1, CTNNB1, EGFR, FGFR2, KRAS
23
Show member pathways
9.3CDH1, CTNNB1, EGFR, KRAS, MUC1, TP53
24
Show member pathways
9.2CDH1, CTNNB1, EGFR, FGFR2, KRAS, TP53
259.2CDH1, CTNNB1, EGFR, FGFR2, KRAS, TP53
269.2CDH1, CTNNB1, EGFR, KRAS, RASGEF1A, TP53
279.1CDH1, EPCAM, KRT19, KRT20, KRT7, MUC1
28
Show member pathways
8.5CTNNB1, EGFR, FGFR2, KRAS, KRT19, KRT20
29
Show member pathways
8.3ADAM17, CDH1, CTNNB1, EGFR, FGFR2, IDH1
30
Show member pathways
7.9ADAM17, CDH1, CTNNB1, EGFR, FGFR2, IDH1

GO Terms for genes affiliated with Intrahepatic Cholangiocarcinoma

About this section

Cellular components related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1catenin complexGO:001634210.8CDH1, CTNNB1
2flotillin complexGO:001660010.6CDH1, CTNNB1
3Golgi lumenGO:000579610.2MUC1, MUC2, MUC4, MUC5AC
4lateral plasma membraneGO:00163289.8CDH1, CTNNB1, EPCAM
5extracellular exosomeGO:00700628.9CDH1, CTNNB1, EPCAM, IDH1, IDH2, KRT19

Biological processes related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

(show all 14)
idNameGO IDScoreTop Affiliating Genes
1maintenance of gastrointestinal epitheliumGO:003027710.9MUC2, MUC4
2glyoxylate cycleGO:000609710.9IDH1, IDH2
3isocitrate metabolic processGO:000610210.9IDH1, IDH2
4cellular response to indole-3-methanolGO:007168110.7CDH1, CTNNB1
5entry of bacterium into host cellGO:003563510.7CDH1, CTNNB1
6lung-associated mesenchyme developmentGO:006048410.7CTNNB1, FGFR2
7mesenchymal cell proliferation involved in lung developmentGO:006091610.7CTNNB1, FGFR2
8morphogenesis of embryonic epitheliumGO:001633110.7CTNNB1, FGFR2
9positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycleGO:003165910.6ADAM17, EGFR
10epidermal growth factor receptor signaling pathwayGO:000717310.6ADAM17, EGFR, KRAS
11O-glycan processingGO:001626610.4MUC1, MUC2, MUC4, MUC5AC
12phosphatidylinositol-mediated signalingGO:004801510.2EGFR, FGFR2, MUC5AC, TP53
13stimulatory C-type lectin receptor signaling pathwayGO:00022239.6KRAS, MUC1, MUC2, MUC4, MUC5AC
14positive regulation of cell proliferationGO:00082849.5ADAM17, CDX2, CTNNB1, EGFR, EPCAM, FGFR2

Molecular functions related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1isocitrate dehydrogenase (NADP+) activityGO:000445010.7IDH1, IDH2
2isocitrate dehydrogenase activityGO:000444810.7IDH1, IDH2
3protein phosphatase bindingGO:00199039.8CTNNB1, EGFR, TP53

Sources for Intrahepatic Cholangiocarcinoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet